26
|
Wissner JL, Schelle JT, Escobedo‐Hinojosa W, Vogel A, Hauer B. Front Cover Picture: Semi‐Rational Engineering of Toluene Dioxygenase from
Pseudomonas putida
F1 towards Oxyfunctionalization of Bicyclic Aromatics (Adv. Synth. Catal. 21/2021). Adv Synth Catal 2021. [DOI: 10.1002/adsc.202100532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
27
|
Vogel A, Saborowski A, Hinrichs J, Ettrich T, Ehmer U, Martens U, Mekolli A, De Toni E, Berg T, Geißler M, Maenz M, Kirstein M, Waldschmidt D. LBA37 IMMUTACE: A biomarker-orientated, multi center phase II AIO study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate stage hepatocellular carcinoma (HCC). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.2114] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
28
|
Vogel A, Behringer D, Bröckling S, Chater J, Derigs HG, Fietz T, Götze T, Hartmann F, Lutz M, Müller L, Moosmann N, Moulin JC, Potenberg J, Saborowski A, Späth-Schwalbe E, Schuler M, Pauligk C, Westphalen C, Zäpf B, Al-Batran SE. 1871TiP PLATON – “Platform for Analyzing Targetable Tumor Mutations”: A pilot study. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.758] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
29
|
Laethem JLV, Borbath I, Karwal M, Verslype C, Van Vlierberghe H, Kardosh A, Zagonel V, Stal P, Sarker D, Palmer D, Vogel A, Edeline J, Cattan S, Kudo M, Cheng AL, Ogasawara S, Siegel A, Chisamore M, Wang A, Zhu A. 933P Updated results for pembrolizumab (pembro) monotherapy as first-line therapy for advanced hepatocellular carcinoma (HCC) in the phase II KEYNOTE-224 study. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
30
|
Bekaii-Saab T, Valle J, Van Cutsem E, Rimassa L, Furuse J, Ioka T, Macarulla T, Bridgewater J, Wasan H, Borad M, Vogel A, Lihou C, Zhen H, Jiang P, Langmuir P, Melisi D. P-113 FIGHT-302: Phase 3 study of first-line pemigatinib vs gemcitabine + cisplatin for cholangiocarcinoma with FGFR2 fusions or rearrangement. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.05.168] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
31
|
Huynh J, Cho M, Kim E, Ren M, Amaya-Chanaga C, Vogel A. P-78 Post hoc analysis in patients with unresectable hepatocellular carcinoma who progressed to Child-Pugh B liver function in the phase 3 REFLECT study of lenvatinib vs sorafenib. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.05.133] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
32
|
Abou-Alfa G, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, Paulson A, Borad M, Gallinson D, Murphy A, Oh D, Dotan E, Catenacci D, Van Cutsem E, Lihou C, Ren H, Bibeau K, Feliz L, Vogel A. SO-4 Progression-free survival in patients with cholangiocarcinoma with FGFR2 fusions or rearrangements: A FIGHT-202 post-hoc analysis of prior systemic therapy response. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.05.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
33
|
Stintzing S, Hübner G, Schröder J, Kisro J, Welslau M, Bürkle D, Göhler T, Schmidt B, Müller-Huesmann H, Krammer-Steiner B, von der Heyde E, Reichenbach F, Arnold D, Gerger A, Hegewisch-Becker S, Vogel A, Winder T, Prager G. P-58 Encorafenib and cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal carcinoma: A multi-centric, multi-national, prospective, longitudinal, non-interventional study in Germany and Austria – BERING CRC. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.05.113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
34
|
Raghav K, Yoshino T, Taniguchi H, Tejpar S, Vogel A, Wainberg Z, Yamaguchi K, Fakih M, Pedersen K, Bando K, Kawakami H, Beck J, Kanai M, Liu Y, Mekan S, Pudussery G, Qiu Y, Kopetz S. P-45 An open-label, phase 2 study of patritumab deruxtecan in patients with previously treated advanced/metastatic colorectal cancer. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.05.100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
35
|
Vogel A, Zhu A, Cheng A, Yau T, Zhou J, Kim E, Malhotra U, Siegel A, Kudo M. Abstract No. 210 KEYNOTE-937 trial in progress: adjuvant pembrolizumab for hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation. J Vasc Interv Radiol 2021. [DOI: 10.1016/j.jvir.2021.03.216] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
36
|
Levy J, David E, Hopkins T, Morris J, Tran N, Farid H, Massari F, O’Connell W, Vogel A, Gangi A, Sunenshine P, Dixon R, Bagla S. Abstract No. 78 Improvement in quality of life in patients treated for painful osseous metastases with radiofrequency ablation: the OPuS One study. J Vasc Interv Radiol 2021. [DOI: 10.1016/j.jvir.2021.03.501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
37
|
Wissner JL, Schelle JT, Escobedo‐Hinojosa W, Vogel A, Hauer B. Semi‐Rational Engineering of Toluene Dioxygenase from
Pseudomonas putida
F1 towards Oxyfunctionalization of Bicyclic Aromatics. Adv Synth Catal 2021. [DOI: 10.1002/adsc.202100296] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
|
38
|
Vogel A, Martinelli E. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Ann Oncol 2021; 32:801-805. [PMID: 33716105 DOI: 10.1016/j.annonc.2021.02.014] [Citation(s) in RCA: 195] [Impact Index Per Article: 65.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2020] [Revised: 02/16/2021] [Accepted: 02/17/2021] [Indexed: 12/13/2022] Open
|
39
|
Vogel A, Brouqui P, Boudjema S. Disinfection of gloved hands during routine care. New Microbes New Infect 2021; 41:100855. [PMID: 33854786 PMCID: PMC8025050 DOI: 10.1016/j.nmni.2021.100855] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2020] [Revised: 02/04/2021] [Accepted: 02/22/2021] [Indexed: 11/16/2022] Open
Abstract
Healthcare-associated infections are a major issue in public health. After several decades of hand hygiene programmes, it is time to admit that we have failed to achieve our goal. One of the reasons is the overuse of gloves, which is in part justified by the nature of the nursing care. Several experimental studies supported the effectiveness of disinfecting gloves, but evidence for routine feasibility and effectiveness is lacking. The aim of this study was to evaluate the effectiveness of alcohol-based disinfection of gloves during nursing care. Swabs were taken from the most contaminated part of both hands at different times: T0 (before wearing gloves), T10 (after 10 minutes of nursing care) from both gloves, T10A (just after the gloves were disinfected for 30 seconds with bedside disposable hydroalcoholic solution) and when possible at T20 and T20A. After 10 minutes of nursing care, gloves were contaminated in 72.5% of cases. After alcohol-based disinfection, gloves became free of microorganism in 79.3% of cases. Alcohol-based disinfection of gloves during routine care is effective and appears to be a reasonable alternative to current recommendations.
Collapse
|
40
|
Wissner JL, Escobedo-Hinojosa W, Vogel A, Hauer B. An engineered toluene dioxygenase for a single step biocatalytical production of (-)-(1S,2R)-cis-1,2-dihydro-1,2-naphthalenediol. J Biotechnol 2020; 326:37-39. [PMID: 33359214 DOI: 10.1016/j.jbiotec.2020.12.007] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2020] [Revised: 12/10/2020] [Accepted: 12/11/2020] [Indexed: 10/22/2022]
Abstract
cis-1,2-Dihydro-1,2-naphthalenediol (DHND) is a valuable molecule employed for the pharmaceutical synthesis of bioactive compounds, such as bicyclic conduritol analogues. Enantiopure (+)-(1R,2S)-DHND (>98 % ee) is easily biosynthesized through the dearomatizing dihydroxylation of naphthalene, catalyzed by toluene dioxygenase (TDO) from Pseudomonas putida F1. However, the opposite enantiomer (-)-(1S,2R)-DHND could not be directly accessed, neither by chemical synthesis nor via biocatalytic approaches. Herein, we report a one-step biosynthesis of the opposite enantiomer (-)-(1S,2R)-DHND in a recombinant TDO E. coli BW25113 platform. We based on a semi-rational approach to generate a set of TDO variants, targeting exclusively the hotspot position F366, in order to enable an enantiomeric switch in the generated product. Eight out of nine single point variants were active and showed not only an alteration in enantioselectivity, but also generated an enantiomeric excess of the pursued product. Variant TDOF366V outperformed above the rest of the set, enabling the synthesis of (-)-(1S,2R)-DHND not only with an excellent enantiomeric excess of 90 %, but also with an advantageous product formation. A comparative semi-preparative biosynthesis yielded, 287 mg of (+)-(1R,2S)-DHND (>98 % ee) and 101 mg of (-)-(1S,2R)-DHND (90 % ee), when performed in a total volume of 100 mL with TDO wild-type and TDOF366V resting cells, respectively.
Collapse
|
41
|
Dewald CLA, Becker LS, Maschke SK, Meine TC, Alten TA, Kirstein MM, Vogel A, Wacker FK, Meyer BC, Hinrichs JB. Percutaneous isolated hepatic perfusion (chemosaturation) with melphalan following right hemihepatectomy in patients with cholangiocarcinoma and metastatic uveal melanoma: peri- and post-interventional adverse events and therapy response compared to a matched group without prior liver surgery. Clin Exp Metastasis 2020; 37:683-692. [PMID: 33034815 PMCID: PMC7666275 DOI: 10.1007/s10585-020-10057-9] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2020] [Accepted: 09/25/2020] [Indexed: 01/15/2023]
Abstract
To evaluate feasibility, frequency and severity of peri-procedural complications and post-procedural adverse events (AEs) in patients with advanced cholangiocarcinoma or liver metastasis of uveal melanoma and prior hemihepatectomy undergoing chemosaturation percutaneous hepatic perfusion (CS-PHP) and to analyze therapy response and overall survival compared to a matched group without prior surgery. CS-PHP performed between 10/2014 and 02/2018 were retrospectively assessed. To determine peri-procedural safety and post-procedural adverse events, hospital records and hematological, hepatic and biliary function were categorized using Common Terminology Criteria for Adverse Events (CTCAE) v5.0 (1–5; mild-death). Significance was tested using Wilcoxon signed-rank and Mann–Whitney U test. Kaplan–Meier estimation and log-rank test assessed survival. Overall 21 CS-PHP in seven patients (4/7 males; 52 ± 10 years) with hemihepatectomy (grouphemihep) and 22 CS-PHP in seven patients (3/7 males; 63 ± 12 years) without prior surgery (groupnoresection) were included. No complications occurred during the CS-PHP procedures. Transient changes (CTCAE grade 1–2) of liver enzymes and blood cells followed all procedures. In comparison, grouphemihep presented slightly more AEs grade 3–4 (e.g. thrombocytopenia in 57% (12/21) vs. 41% (9/22; p = 0.37)) 5–7 days after CS-PHP. These AEs were self-limiting or responsive to treatment (insignificant difference of pre-interventional to 21–45 days post-interventional values (p > 0.05)). One patient in grouphemihep with high tumor burden died eight days following CS-PHP. No deaths occurred in groupnoresection. In comparison, overall survival after first diagnosis was insignificantly shorter in groupnoresection (44.7(32–56.1) months) than in grouphemihep (48.3(34.6–72.8) months; p = 0.48). The severity of adverse events following CS-PHP in patients after hemihepatectomy was comparable to a matched group without prior liver surgery. Thus, the performance of CS-PHP is not substantially compromised by a prior hemihepatectomy.
Collapse
|
42
|
Droz Dit Busset M, Shaib W, Harris W, Damjanov N, Borad M, Vogel A, Bridgewater J, Sellmann L, Dadduzio V, Borner M, Snider J, Cantero F, Saulay M, Braun S, Mazzaferro V, Javle M. 45P Efficacy of derazantinib in intrahepatic cholangiocarcinoma patients with FGFR2 mutations or amplifications: Pooled analysis of clinical trials and early access programs. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.2204] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
43
|
Bartsch S, Brummund J, Köpke S, Straatman H, Vogel A, Schürmann M. Optimization of Alcohol Dehydrogenase for Industrial Scale Oxidation of Lactols. Biotechnol J 2020; 15:e2000171. [DOI: 10.1002/biot.202000171] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
44
|
Götze T, Hofheinz R, Reichart A, Pauligk C, Schlag R, Siegler G, Hoeffkes HG, Blau W, Homann N, Trojan J, Waidmann O, Pink D, Messmann H, Kunzmann V, Vogel A, Ettrich T, Schönherr C, Schaaf M, zur Hausen G, Al-Batran SE. 1525O The QOLIXANE trial - Real life QoL and efficacy data in 1st line pancreatic cancer from the prospective platform for outcome, quality of life, and translational research on pancreatic cancer (PARAGON) registry. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.2008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
45
|
Llovet J, El-Khoueiry A, Vogel A, Madoff D, Finn R, Ogasawara S, Ren Z, Mody K, Li JJ, Siegel A, Dubrovsky L, Kudo M. 1016TiP LEAP-012 trial in progress: Pembrolizumab plus lenvatinib and transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC) not amenable to curative treatment. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1132] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
46
|
Vogel A, Merle P, Verslype C, Finn R, Zhu A, Cheng AL, Chan S, Yau T, Ryoo BY, Wei Z, Malhotra U, Siegel A, Kudo M. 1003P Baseline (BL) liver function and outcomes in patients (pts) with unresectable hepatocellular carcinoma (HCC) in KEYNOTE-240. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1119] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
47
|
Vogel A, Müller D, De Toni E, Siegler G, Siebler J, Lindig U, Müller T, Schultheiss M, Geißler M, Krammer-Steiner B, Reichart A, Lammert F, Prause C, Walker M, Al-Batran SE, Kosic N. 988P Safety analysis of the run-in phase (1st and 2nd cohort) of the IMMUNIB trial (AIO-HEP-0218/ass) - An open-label, single-arm phase II study evaluating safety and efficacy of immunotherapy with nivolumab in combination with lenvatinib in advanced stage HCC. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1104] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
48
|
Vogel A, Finn R, Kelley R, Furuse J, Edeline J, Ren Z, Su S, Malhotra U, Siegel A, Valle J. P-99 Pembrolizumab in combination with gemcitabine and cisplatin for the treatment of advanced biliary tract cancer: phase 3 KEYNOTE-966 trial in progress. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.04.181] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
49
|
Tassano E, Merusic K, Buljubasic I, Laggner O, Reiter T, Vogel A, Hall M. Regioselective biocatalytic self-sufficient Tishchenko-type reaction via formal intramolecular hydride transfer. Chem Commun (Camb) 2020; 56:6340-6343. [PMID: 32391538 DOI: 10.1039/d0cc02509g] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
A self-sufficient nicotinamide-dependent intramolecular bio-Tishchenko-type reaction was developed. The reaction is catalyzed by alcohol dehydrogenases and proceeds through formal intramolecular hydride transfer on dialdehydes to deliver lactones. Regioselectivity on [1,1'-biphenyl]-2,2'-dicarbaldehyde substrates could be controlled via the electronic properties of the substituents. Preparative scale synthesis provided access to substituted dibenzo[c,e]oxepin-5(7H)-ones.
Collapse
|
50
|
Aalbers FS, Fürst MJ, Rovida S, Trajkovic M, Gómez Castellanos JR, Bartsch S, Vogel A, Mattevi A, Fraaije MW. Approaching boiling point stability of an alcohol dehydrogenase through computationally-guided enzyme engineering. eLife 2020; 9:e54639. [PMID: 32228861 PMCID: PMC7164962 DOI: 10.7554/elife.54639] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2019] [Accepted: 03/30/2020] [Indexed: 12/14/2022] Open
Abstract
Enzyme instability is an important limitation for the investigation and application of enzymes. Therefore, methods to rapidly and effectively improve enzyme stability are highly appealing. In this study we applied a computational method (FRESCO) to guide the engineering of an alcohol dehydrogenase. Of the 177 selected mutations, 25 mutations brought about a significant increase in apparent melting temperature (ΔTm ≥ +3 °C). By combining mutations, a 10-fold mutant was generated with a Tm of 94 °C (+51 °C relative to wild type), almost reaching water's boiling point, and the highest increase with FRESCO to date. The 10-fold mutant's structure was elucidated, which enabled the identification of an activity-impairing mutation. After reverting this mutation, the enzyme showed no loss in activity compared to wild type, while displaying a Tm of 88 °C (+45 °C relative to wild type). This work demonstrates the value of enzyme stabilization through computational library design.
Collapse
|